 |
||||
|
||||
|
||||
|
||||
Previous Article | Next Article
The Journal of Neuroscience, April 1, 2001, 21(7):2247-2255
Caspase-8 Is an Effector in Apoptotic Death of Dopaminergic Neurons in Parkinson's Disease, But Pathway Inhibition Results in Neuronal Necrosis
Andreas Hartmann1, Jean-Denis Troadec1, Stéphane Hunot1, Kristy Kikly2, Baptiste A. Faucheux1, Annick Mouatt-Prigent1, Merle Ruberg1, Yves Agid1, and Etienne C. Hirsch1 1 Institut National de la Santé et de la Recherche Médicale U289, Hôpital de la Salpêtière, 75013 Paris, France, and 2 SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-0939
Caspase-8 is a proximal effector protein of the tumor necrosis factor receptor family death pathway. In the present human postmortem study, we observed a significantly higher percentage of dopaminergic (DA) substantia nigra pars compacta neurons that displayed caspase-8 activation in Parkinson's disease (PD) patients compared with controls. In an in vivo experimental PD model, namely subchronically 1,2,3,6-tetrahydropyridine-treated mice, we also show that caspase-8 is indeed activated after exposure to this toxin early in the course of cell demise, suggesting that caspase-8 activation precedes and is not the consequence of cell death. However, cotreatment of 1-methyl-4-phenylpyridinium-intoxicated primary DA cultures with broad-spectrum and specific caspase-8 inhibitors did not result in neuroprotection but seemed to trigger a switch from apoptosis to necrosis. We propose that this effect is related to ATP depletion and suggest that the use of caspase inhibitors in pathologies linked to intracellular energy depletion, such as PD, should be cautiously evaluated.
Key words: Parkinson's disease; caspase-8; apoptosis; necrosis; ATP; MPTP
Copyright © 2001 Society for Neuroscience 0270-6474/01/2172247-09$05.00/0
This article has been cited by other articles:
L.-y. Yu, M. Saarma, and U. Arumae
Death Receptors and Caspases But Not Mitochondria Are Activated in the GDNF- or BDNF-Deprived Dopaminergic Neurons
J. Neurosci., July 23, 2008; 28(30): 7467 - 7475.
[Abstract] [Full Text] [PDF]
The Parkinson Study Group PRECEPT Investigators
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
Neurology, October 9, 2007; 69(15): 1480 - 1490.
[Abstract] [Full Text] [PDF]
B. Sredni, R. Geffen-Aricha, W. Duan, M. Albeck, F. Shalit, H. M. Lander, N. Kinor, O. Sagi, A. Albeck, S. Yosef, et al.
Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models
FASEB J, June 1, 2007; 21(8): 1870 - 1883.
[Abstract] [Full Text] [PDF]
S. Ramachandiran, J. M. Hansen, D. P. Jones, J. R. Richardson, and G. W. Miller
Divergent Mechanisms of Paraquat, MPP+, and Rotenone Toxicity: Oxidation of Thioredoxin and Caspase-3 Activation
Toxicol. Sci., January 1, 2007; 95(1): 163 - 171.
[Abstract] [Full Text] [PDF]
F. Blandini, E. Sinforiani, C. Pacchetti, A. Samuele, E. Bazzini, R. Zangaglia, G. Nappi, and E. Martignoni
Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease
Neurology, February 28, 2006; 66(4): 529 - 534.
[Abstract] [Full Text] [PDF]
P. Jenner
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease
Neurology, October 12, 2004; 63(7_suppl_2): S13 - S22.
[Full Text]
W.-S. Choi, D.-S. Eom, B. S. Han, W. K. Kim, B. H. Han, E.-J. Choi, T. H. Oh, G. J. Markelonis, J. W. Cho, and Y. J. Oh
Phosphorylation of p38 MAPK Induced by Oxidative Stress Is Linked to Activation of Both Caspase-8- and -9-mediated Apoptotic Pathways in Dopaminergic Neurons
J. Biol. Chem., May 7, 2004; 279(19): 20451 - 20460.
[Abstract] [Full Text] [PDF]
X. Zheng, P. M. Chou, B. L. Mirkin, and A. Rebbaa
Senescence-initiated Reversal of Drug Resistance: Specific Role of Cathepsin L
Cancer Res., March 1, 2004; 64(5): 1773 - 1780.
[Abstract] [Full Text] [PDF]
S. Hayley, S. J. Crocker, P. D. Smith, T. Shree, V. Jackson-Lewis, S. Przedborski, M. Mount, R. Slack, H. Anisman, and D. S. Park
Regulation of Dopaminergic Loss by Fas in a 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease
J. Neurosci., February 25, 2004; 24(8): 2045 - 2053.
[Abstract] [Full Text] [PDF]
S. Kahns, M. Kalai, L. D. Jakobsen, B. F. C. Clark, P. Vandenabeele, and P. H. Jensen
Caspase-1 and Caspase-8 Cleave and Inactivate Cellular Parkin
J. Biol. Chem., June 20, 2003; 278(26): 23376 - 23380.
[Abstract] [Full Text] [PDF]
B. S. Han, H.-S. Hong, W.-S. Choi, G. J. Markelonis, T. H. Oh, and Y. J. Oh
Caspase-Dependent and -Independent Cell Death Pathways in Primary Cultures of Mesencephalic Dopaminergic Neurons after Neurotoxin Treatment
J. Neurosci., June 15, 2003; 23(12): 5069 - 5078.
[Abstract] [Full Text] [PDF]
S. J. Crocker, P. D. Smith, V. Jackson-Lewis, W. R. Lamba, S. P. Hayley, E. Grimm, S. M. Callaghan, R. S. Slack, E. Melloni, S. Przedborski, et al.
Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease
J. Neurosci., May 15, 2003; 23(10): 4081 - 4091.
[Abstract] [Full Text] [PDF]
A. Benchoua, C. Couriaud, C. Guegan, L. Tartier, P. Couvert, G. Friocourt, J. Chelly, J. Menissier-de Murcia, and B. Onteniente
Active Caspase-8 Translocates into the Nucleus of Apoptotic Cells to Inactivate Poly(ADP-ribose) Polymerase-2
J. Biol. Chem., September 6, 2002; 277(37): 34217 - 34222.
[Abstract] [Full Text] [PDF]
J. Bilsland, S. Roy, S. Xanthoudakis, D. W. Nicholson, Y. Han, E. Grimm, F. Hefti, and S. J. Harper
Caspase Inhibitors Attenuate 1-Methyl-4-Phenylpyridinium Toxicity in Primary Cultures of Mesencephalic Dopaminergic Neurons
J. Neurosci., April 1, 2002; 22(7): 2637 - 2649.
[Abstract] [Full Text] [PDF]
V. Viswanath, Y. Wu, R. Boonplueang, S. Chen, F. F. Stevenson, F. Yantiri, L. Yang, M. F. Beal, and J. K. Andersen
Caspase-9 Activation Results in Downstream Caspase-8 Activation and Bid Cleavage in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease
J. Neurosci., December 15, 2001; 21(24): 9519 - 9528.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|